Abstract:V600E BRAF have been identified as new promising targets for the design of novel anticancer agents. It is reported that the inhibitors based on 2,3-dihydroimidazo[4,5]pyridin-2-one scaffold and a meta -substituted middle ring exhibit potent inhibitory activities toward V600E BRAF. To investigate how their chemical structures relate to the inhibitory activities and to identify the key structural elements that are required in the rational design of potential drug candidates of this class, molecular docking simulations and three-dimensional quantitative structure–activity relationship (3D-QSAR) methods were performed. The bioactive conformation was explored by docking one potent compound 1 into the active site of BRAF in its DFG-out inactive conformation. The constructed CoMFA and CoMSIA models produced statistically significant results with the cross-validated correlation coefficients q 2 of 0.563 and 0.624, non-cross-validated correlation coefficients r 2 of 0.982 and 0.962, and predicted correction coefficients r pred 2 of 0.822 and 0.875, respectively. In addition, the CoMFA and CoMSIA models were used to guide the design of a series of new inhibitors of this class with predicted excellent activities. Thus, these models may be used as an efficient tool to predict the inhibitory activities and to guide the future rational design of 2,3-dihydroimidazo[4,5]pyridin-2-one derivatives with a meta substitution pattern as BRAF inhibitors with potent activities.

Three dimensional quantitative structure-activity relationship of DATA analogues as HIV-1 reverse transcriptase inhibitors

Three Dimensional Quantitative Structure-activity Relationship of HEPT Analogues As HIV-1 Reverse Transcriptase Inhibitors

Revealing The Drug-Resistant Mechanism For Diarylpyrimidine Analogue Inhibitors Of Hiv-1 Reverse Transcriptase

Docking and field-based QSAR studies of S-DABOs as HIV-1 reverse transcriptase inhibitors

Quantitatives Structure-Activity Relationship and Modification of HIV Protease Inhibitors

Quantitative Structure-Activity Relationships of Hiv-1 Integrase Inhibitors of Dkas

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

Theoretical Study on Anti-mutant HIV-1 Virus Activity of Diaryltriazine Analogs

Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors Ⅱ 3D-QSAR Study on 6-(1-naphthylmethyl)substituted Thymines

[Quantitative Structure-Activity Relationship Study of Tetrahydroimidazobenzodiazepinone Anti-Hiv Drug Using Three-Dimensional Holographic Vector of Atomic Interaction Field].

Docking-based CoMFA and CoMSIA Studies on Naphthyl-Substituted Diarylpyrimidines As NNRTIs.

Multi-target QSAR study in the analysis and design of HIV-1 inhibitors

Docking Field-Based QSAR and Pharmacophore Studies on the Substituted Pyrimidine Derivatives Targeting HIV-1 Reverse Transcriptase

QSAR Studies of Anti-HIV Drug HEPT Using 3D-Hovaif

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

3D-QSAR Study for Inhibitors of Cyclin-Dependent Kinase 4

Drug Resistant Mechanism of Diaryltriazine Analog Inhibitors of HIV‐1 Reverse Transcriptase Using Molecular Dynamics Simulation and 3D‐QSAR

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Structural Determination of Three Different Series of Compounds as Hsp90 Inhibitors Using 3D-QSAR Modeling, Molecular Docking and Molecular Dynamics Methods

Virtual Screening, Biological Evaluation, And 3d-Qsar Studies Of New Hiv-1 Entry Inhibitors That Function Via The Cd4 Primary Receptor

Identification of new potential HIV-1 reverse transcriptase inhibitors by QSAR modeling and structure-based virtual screening